Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ann Arbor Stage II Marginal Zone Lymphoma: early-phase trial registry
1 of 2 indexed Ann Arbor Stage II Marginal Zone Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Ann Arbor Stage II Marginal Zone Lymphoma: 2 US clinical trials tracked, 1 recruiting.
Ann Arbor Stage II Marginal Zone Lymphoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Washington, running 1 of these trials.
Enrollment posture brief
Registry condition ann-arbor-stage-ii-marginal-zone-lymphoma
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Ann Arbor Stage II Marginal Zone Lymphoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ann Arbor Stage II Marginal Zone Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ann Arbor Stage II Marginal Zone Lymphoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
University of Washington
NCT06442475
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Mayo Clinic
NCT04323956
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Ann Arbor Stage II Marginal Zone Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ann Arbor Stage II Marginal Zone Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ann Arbor Stage II Marginal Zone Lymphoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Ann Arbor Stage II Marginal Zone Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Washington sponsors the most Ann Arbor Stage II Marginal Zone Lymphoma trials on record, review their full trial history before evaluating a specific study. See University of Washington's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ann Arbor Stage II Marginal Zone Lymphoma condition card totals 2 registered trials; most-linked intervention Parsaclisib; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.